MeiraGTx Holdings PLC
$ 7.70
2.12%
24 Feb - close price
- Market Cap 619,780,000 USD
- Current Price $ 7.70
- High / Low $ 7.89 / 7.57
- Stock P/E N/A
- Book Value -0.50
- EPS -2.11
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -6.11 %
- 52 Week High 9.73
- 52 Week Low 4.55
About
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Analyst Target Price
$26.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-12 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-03-14 | 2023-11-14 | 2023-08-10 | 2023-05-11 | 2023-03-14 |
| Reported EPS | -0.62 | -0.48 | -0.51 | -0.5 | -0.55 | -0.76 | -0.32 | -0.42 | -0.74 | -0.53 | -0.62 | -0.6 |
| Estimated EPS | -0.5 | -0.4733 | -0.5 | -0.56 | -0.52 | -0.4 | -0.5 | -0.11 | -0.55 | -0.57 | -0.66 | -0.49 |
| Surprise | -0.12 | -0.0067 | -0.01 | 0.06 | -0.03 | -0.36 | 0.18 | -0.31 | -0.19 | 0.04 | 0.04 | -0.11 |
| Surprise Percentage | -24% | -1.4156% | -2% | 10.7143% | -5.7692% | -90% | 36% | -281.8182% | -34.5455% | 7.0175% | 6.0606% | -22.449% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGTX
2026-02-22 03:33:04
这篇文章探讨了抗衰老市场作为下一个投资热点，指出全球抗衰老行业规模正不断增长。文章推荐了五只在美国上市的抗衰老股票，分别是MeiraGTx Holdings, Acumen Pharmaceuticals, Lineage Cell Therapeutics, Celularity, 和Unity Biotechnology，并简要介绍了它们在研项目和市场表现。这些公司主要通过基因疗法、生物制药和干细胞技术开发治疗老年疾病和退行性疾病的药物。
2026-02-19 13:44:00
This article analyzes Meiragtx Holdings Plc (NASDAQ: MGTX), noting a divergent sentiment across all time horizons and suggesting choppy conditions. It highlights an exceptional 60.5:1 risk-reward short setup and provides institutional trading strategies tailored to different risk profiles, including position, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
2026-02-19 08:28:13
MeiraGTx Holdings PLC (NASDAQ:MGTX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $26.00. While some analysts have issued "sell" ratings, the majority have given "buy" or "strong buy" recommendations. The company's stock currently trades at $7.51, with a market capitalization of $604.48 million, and institutional investors hold 67.48% of the shares.
2026-02-18 16:48:57
MeiraGTx (NASDAQ:MGTX) recently traded up 1.7% to $7.58, though with lower-than-average volume, and currently holds a "Moderate Buy" consensus from analysts with an average price target of $26.00. The clinical-stage gene therapy company has a market cap of $610.11 million, but also faces weak liquidity and a high debt-to-equity ratio. While hedge funds have adjusted their positions, MarketBeat suggests that top analysts recommend other stocks over MGTX.
2026-02-08 12:36:00
This article from Stock Traders Daily discusses Meiragtx Holdings Plc (NASDAQ: MGTX), highlighting a weak near-term sentiment despite long-term strength. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis for different horizons.
2026-02-06 11:01:38
MeiraGTx has licensed a complement-targeted geographic atrophy program from ZipBio, focusing on AI-designed protein therapeutics for this severe form of age-related macular degeneration. While current FDA-approved therapies show modest benefits, this deal highlights ongoing efforts to find more durable treatments for GA, though no clinical data for ZipBio's therapies are yet available. The agreement underscores the potential of gene therapy and novel protein therapeutics in addressing the significant unmet need in GA treatment.
